Kyntra Bio (KYNB) Assets (2014 - 2026)

Kyntra Bio has disclosed Assets across 13 years of filings, most recently posting $101.1 million for Q2 2026.

• In Q2 2026, Assets fell 43.23% year-over-year to $101.1 million; the TTM figure through Jun 2026 stood at $101.1 million (down 43.23% YoY), while the FY2025 annual figure was $119.6 million, down 44.25% from the prior year.
• Assets came in at $101.1 million for Q2 2026 at Kyntra Bio, down from $109.6 million in the prior quarter.
• In the past five years, Assets ranged from a high of $745.9 million in Q1 2022 to a low of $101.1 million in Q2 2026.
• Average Assets over 5 years is $363.2 million, with a median of $329.5 million recorded in 2024.
• Year-over-year, Assets dropped 5.25% in 2022 and slumped 54.84% in 2025.
• Over 5 years, Assets stood at $610.1 million in 2022, then plunged by 30.58% to $423.5 million in 2023, then plunged by 49.35% to $214.5 million in 2024, then slumped by 44.25% to $119.6 million in 2025, then declined by 15.48% to $101.1 million in 2026.
• Per Business Quant data, the three most recent Assets figures were $101.1 million in Q2 2026, $109.6 million in Q1 2026, and $119.6 million in Q4 2025.